Wall Street Firms Tout Corcept Therapeutics Incorporated (CORT) Prospects on Korlym Medication Prospects

Corcept Therapeutics Incorporated (NASDAQ:CORT) is one of the champion biotech stocks to bargain according to Wall Street analysts. On November 25, H.C. Wainwright reiterated a Buy standing and a $145 terms people connected the stock, citing its beardown maturation prospects contempt commercialized challenges.

The probe steadfast has reiterated its assurance successful the company’s Korlym medication, whose income are projected to turn by 19% to 26% twelvemonth implicit year, affirming the underlying beardown demand. Volume has accrued by 40% implicit the past 2 quarters, and the institution is poised to conscionable its guidance of $800-$850 million.

Likewise, Corcept is simply a Buy owing to a beardown equilibrium expanse that supports the motorboat of 2 products adjacent year. The institution is connected the cusp of launching relacorilant for Cushing’s syndrome, with income expected to scope $4.3 cardinal by 2034.

On November 17, Wolfe Research began sum of Corcept Therapeutics (NASDAQ: CORT) with a Peer Perform standing and said it expects the banal to commercialized successful the $70- $75 scope until the company’s patent litigation and antitrust cases are settled. Analyst Kalpit Patel pointed to these ineligible issues arsenic near-term hurdles but besides noted the imaginable boost from relacorilant, which has a PDUFA day for hypercortisolism connected December 30, 2025. Although the steadfast sees committedness successful the drug, Wolfe Research remains much cautious connected its highest income outlook than the broader market.

Corcept Therapeutics Incorporated (NASDAQ:CORT) develops drugs that modulate the accent hormone cortisol to dainty terrible metabolic, oncologic (cancer), and neuropsychiatric disorders, with their archetypal approved drug, Korlym, treating Cushing’s Syndrome, and their pipeline exploring treatments for cancers, ALS, and liver diseases.

While we admit the imaginable of CORT arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 12 Best Consumer Goods Stocks Billionaires Are Quietly Buying and Goldman Sachs Penny Stocks: Top 12 Stock Picks.

Disclosure: None. This nonfiction is primitively published at Insider Monkey.